Clinical Trials Administrator Archives – May 1, 2007
May 1, 2007
View Archives Issues
-
Personalized immunotherapy research leads to more complex clinical trials
A new approach to personalized medicine is resulting in phase I and phase II clinical trials that rely on extensive, hands-on investigator and clinical research (CR) staff training, and these types of studies are creating both new challenges and opportunities for North American CR sites. -
Personalized immunotherapy clinical trials in practice
As the medical industry increasingly moves toward personalized medicine, there will be challenges for clinical trial sites that adapt to these types of studies. -
Network encourages close ties to patients
Investigators working in a rare disease field often find that it's an uphill climb to recruit participants, obtain funding, and interest peers in the work. -
New and improved data collection methods
Clinical research sites involved in the Rare Diseases Clinical Research Network (RDCRN) have numerous advantages from the collaborative work, including the ability to access a data and technology coordinating center (DTCC). -
Attention to details when improving recruitment
Even for research professionals for whom clinical trial recruitment is fun, the nuances can be challenging. -
Researchers have more training opportunities
When the National Institutes of Health (NIH) established the Rare Diseases Clinical Research Network (RDCRN) in 2003 with $51 million in grant funding over five years, one of the NIH's stated goals was to train the next generation of investigators.